In this study, pancreatic and liver fat accumulations were assessed in patients with type 2 diabetes before and after treatment with SGLT‐2 inhibitors, then the effect of SGLT‐2 inhibitors on these fat accumulations were evaluated. Here, SLC5A2 is linked to type 2 diabetes mellitus.